The main objective of the research was to determine the key precedents for decision-making and acceptability of evidence in all previously completed NICE HST appraisals. The primary goal of the research was to equip manufacturers with tangible insights, which could be utilised to improve the likelihood of a positive recommendation and timely patient access.
We conducted a comprehensive search of the NICE website in May 2024, reviewing all completed HST appraisals from 2015 to present date. These appraisals were assessed for multiple criteria, including NICE recommendations, pricing arrangements, inclusion of carer disutility, 1.5% discount rates, QoL sources, and QALY weighting. The data was analysed to identify key trends, offering manufacturers strategies to navigate the HST process effectively.
Will Wright, Yasmin Bappoo, Mark Burton and I worked closely to identify the optimal approach to extraction and explored the most useful data points that would be most beneficial for the preparation of manufacturers seeking to achieve patient access.
The key challenge involved anticipating which data points would be most valuable for manufacturers aiming to secure patient access through HSTs in the UK, especially considering the limited evidence base associated with very rare diseases and the rigor of the NICE appraisal process.
Dhanveer is an Associate at FIECON focused on delivering high-quality HEOR and Access solutions. With experience in AMCP dossiers, value communication materials, budget impact modelling, ITCs and systematic literature reviews. His expertise spans a wide range of therapeutic areas, predominantly oncology, eczema and rare diseases.
To learn more about the poster, please visit:https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/144235
